Challenges of infectious diseases in the USA

The Lancet

Volumn 384, Issue 9937, 2014, Pages 53-63

  Khabbaz, Rima F ^a   Moseley, Robin R ^a   Steiner, Riley J ^b   Levitt, Alexandra M ^a   Bell, Beth P ^c  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; BIOINFORMATICS; CHRONIC HEPATITIS; DISEASE TRANSMISSION; FOOD POISONING; GOVERNMENT; HEALTH CARE; HEALTH DISPARITY; HEALTHCARE ASSOCIATED INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFECTION CONTROL; MOLECULAR DIAGNOSTICS; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; TUBERCULOSIS; UNITED STATES; VACCINATION; ZOONOSIS; ENDEMIC DISEASE; INFECTION PREVENTION; NONHUMAN; PREVENTION AND CONTROL; PUBLIC HEALTH;

VACCINE;

ANIMALS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; DISEASE VECTORS; DRUG RESISTANCE, MICROBIAL; HEPATITIS, CHRONIC; HIV INFECTIONS; HUMANS; INCIDENCE; PREVALENCE; PUBLIC HEALTH; SEXUALLY TRANSMITTED DISEASES; TUBERCULOSIS; UNITED STATES; VACCINATION; ZOONOSES;

EID: 84903788645     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60890-4     Document Type: Review

References (128)

1. Lozano R, Naghavi M, Foreman K., et al Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-128.
2. Committee on Microbial Threats to Health, Institute of Medicine. Emerging infections; microbial threats to health in the United States. Washington, DC: National Academies Press, 1992.
3. Morens DM, Fauci AS Emerging infectious diseases in 2012: 20 years after the Institute of Medicine report. mBio 2012; 3: e00494-512.
4. NIAID, NIH. NIH/NIAID/DMID research agenda for emerging diseases. Bethesda, MD: National Institute of Allergy and Infectious Diseases, 1994.
5. Centers for Disease Control and Prevention. Preventing emerging infectious diseases: a strategy for the 21st century. Atlanta: US Department of Health and Human Services, Public Health Service, 1998.
6. Whitney CG, Zhou F, Singleton J., Schuchat A. Benefits from immunization during the vaccines for children program era-United States, 1994-2013. MMWR Morb Mortal Wkly Rep 2014; 63: 352-55.
7. Whitney CG, Pilishvili T, Farley M.M., et al Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006; 368: 1495-502.
8. Pilishvili T, Lexau C, Farley M.M., et al Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32-41.
9. Nuorti JP, Whitney CG, Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and children-use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59 (RR-11): 1-18.
10. Moore M, Link-Gelles R, Farley M., et al Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease, U.S, 2010-11. IDWeek 2012; San Diego, CA: Oct 19, 2012. Abstract number 1219. https://idsa.confex.com/idsa/ 2012/webprogram/Paper36569.html(accessed June 19, 2014)
11. Desai R, Curns AT, Steiner C.A., et al All-cause gastroenteritis and rotavirus-coded hospitalizations among US children, 2000-2009. Clin Infect Dis 2012; 55: e28-34.
12. Tate J, Haynes A, Payne D., et al Trends in national rotavirus activity before and after introduction of rotavirus vaccine into the national immunization program in the United States, 2000-2012. Pediatr Infect Dis J 2013; 32: 741-44.
13. Satterwhite CL, Torrone E, Meites E., et al Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 2013; 40: 187-93.
14. Markowitz LE, Dunne EF, Saraiya M, Lawson H.W., Chesson H., Unger ER, Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Quadrivalent human papillomavirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56 (RR-02): 1-24.
15. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60: 1705-08.
16. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13-17 years-United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61: 671-77.
17. Katz SL, Hinman AR Summary and conclusions: measles elimination meeting, 16-17 March 2000. J Infect Dis 2004; 189 (suppl 1): S43-47.
18. Centers for Disease Control and Prevention. Measles-United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61: 253-57.
19. Gastañaduy P.A., Redd SB, Parker Fiebelkorn A, et al Measles-United States, January 1-May 23, 2014. MMWR; 63: 496-99
20. Chen S.Y., Anderson S, Kutty P.K., et al Healthcare-associated measles outbreak in the United States after an importation: challenges and economic impact. J Infect Dis 2011; 203: 1517-25.
21. Centers for Disease Control and Prevention. Two measles outbreaks after importation-Utah, March-June 2011. MMWR Morb Mortal Wkly Rep 2013; 62: 222-25.
22. Dayan GH, Quinlisk MP, Parker A.A., et al Recent resurgence of mumps in the United States. N Engl J Med 2008; 358: 1580-89.
23. Centers for Disease Control and Prevention. Mumps outbreak at a summer camp-New York, 2005. MMWR Morb Mortal Wkly Rep 2006: 55:175-77.
24. Centers for Disease Control and Prevention. Mumps outbreak on a university campus-California, 2011. MMWR Morb Mortal Wkly Rep 2012; 61: 986-89.
25. Centers for Disease Control and Prevention. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55 (RR-03): 1-34.
26. Winter K, Harriman K, Zipprich J., et al California pertussis epidemic, 2010. J Pediatrics 2012: 161: 1091-96.
27. Centers for Disease Control and Prevention. Pertussis Epidemic-Washington, 2012. MMWR Morb Mortal Wkly Rep 2012; 61: 517-22.
28. Misegades LK, Winter K, Harriman K., et al Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012; 308: 2126-32.
29. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged >12 months-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60: 1424-26.
30. Klevens RM, Edwards J, Richards C., et al Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep 2007; 122: 160-66.
31. Scott RD. The direct medical costs of healthcare-associated infections in U.S. hospitals and the benefits of prevention. Atlanta: Centers for Disease Control and Prevention, 2009.
32. Srinivasan A. Influential outbreaks of healthcare-associated infections in the past decade. Infect Control Hosp Epidemiol 2010: 31: S70-72.
33. Guh AY, Thompson NC, Schaefer M.K., Patel PR, Perz JF Patient notification for bloodborne pathogen testing due to unsafe injection practices in the US health care settings, 2001-2011. Med Care 2012; 50: 785-91.
34. One & Only Campaign. http://www.oneandonlycampaign.org/ (accessed June 18, 2014).
35. Centers for Disease Control and Prevention. Multistate outbreak of fungal meningitis and other infections. Oct 23, 2013. http://www.cdc.gov/hai/ outbreaks/meningitis.html (accessed June 19, 2014).
36. Smith RM, Schaefer MK, Kainer M.A., et al Fungal infections associated with contaminated methylprednisolone injections-preliminary report. N Engl J Med 2013; 369: 1598-1609.
37. Centers for Disease Control and Prevention. Reductions in central line-associated bloodstream infections among patients in intensive care units-Pennsylvania, April 2001-March 2005. MMWR Morb Mortal Wkly Rep 2005; 54: 1013-16.
38. Pronovost P, Needham D, Berenholtz S., et al An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006; 355: 2725-32.
39. Burton DC, Edwards JR, Horan T.C., Jernigan JA, Fridkin SK Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA 2009; 301: 727-36.
40. Kallen AJ, Mu Y, Bullen S., et al. for the Active Bacterial Core surveillance (ABCs) MRSA Investigators of the Emerging Infections Program. Health care-associated invasive MRSA infections, 2005-2008. JAMA 2010; 304: 641-47.
41. Burton DC, Edwards JR, Srinivasan A, Fridkin S.K., Gould CV Trends in catheter-associated urinary tract infections in adult intensive care units-United States, 1990-2007. Infect Control Hosp Epidemiol 2011; 32: 748-56.
42. US Department of Health and Human Services. Action plan to prevent healthcare-associated infections: road map to elimination. June, 2009. http://www.hhs.gov/ash/initiatives/hai/actionplan/hhs-hai-action-plan-final- 06222009.pdf (accessed June 19, 2014).
43. Malpiedi PJ, Peterson KD, Soe M.M., et al 2011 National and state healthcare-associated infection standardized infection ratio report: using data reported to the National Healthcare Safety Network as of September 4, 2012. Published Feb 11, 2013. http://www.cdc.gov/hai/pdfs/SIR/SIR-Report-02-07-2013. pdf (accessed June 19, 2014).
44. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. http://www.cdc.gov/drugresistance/threat-report- 2013/index.html (accessed June 19, 2014).
45. Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009. HCUP statistical brief number 124. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality, 2011. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf (accessed June 19, 2014).
46. Centers for Disease Control and Prevention. Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep 2012; 61: 157-62.
47. Centers for Disease Control and Prevention. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 2013; 62: 165-70.
48. Patel G, Huprikar S, Factor S.H., Jenkins SG, Calfee DP Outcomes of carbapenem-resistant Klebsiella pneumonia infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29: 1099-106.
49. Chitnis AS, Caruthers PS, Rao A.K., et al Outbreak of carbapenem-resistant Enterobacteriaceae at a long-term acute care hospital: sustained reductions in transmissions through active surveillance and targeted interventions. Infect Control Hosp Epidemiol 2012; 33: 984-92.
50. Jones KE, Patel NG, Leva, MA, et al Global trends in emerging infectious diseases. Nature 2008; 4512: 990-94.
51. Centers for Disease Control and Prevention. Hantavirus pulmonary syndrome in visitors to a national park-Yosemite Valley, California, 2012. MMWR Morb Mortal Wkly Rep 2012; 61: 952.
52. Centers for Disease Control and Prevention. Influenza A (H3N2) variant virus-related hospitalizations: Ohio, 2012. MMWR Morb Mortal Wkly Rep 2012; 61: 764-67.
53. Wong KK, Greenbaum A, Moll M.E., et al Outbreak of influenza A (H3N2) variant virus infection among attendees of an agricultural fair, Pennsylvania, USA, 2011. Emerg Infect Dis 2012; 18: 1937-44.
54. Adams S, Sandrock C. Avian influenza: update. Med Princ Pract 2010; 19: 421-32.
55. Gao R, Cao B, Hu Y., et al Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368: 1888-97.
56. Wu S, Wu F, He J. Emerging risk of H7N9 influenza in China. Lancet 2013; 381: 1539-40.
57. Jhung MA, Swerdlow D, Olsen SJ Epidemiology of 2009 pandemic influenza A (H1N1) in the United States. Clin Infect Dis 2011: 52 (suppl 1): S13-S26.
58. Khan G. A novel coronavirus capable of lethal human infections: an emerging picture. Virol J 2013; 10: 66.
59. Lau SK, Woo PC, Li K.S., et al Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA 2005; 102: 14040-45.
60. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) summary and literature update-as of 11 June 2014 (update 16). http://www.who.int/csr/disease/coronavirus-infections/MERS-CoV-summary-update- 20140611.pdf?ua=1 (accessed June 19, 2014).
61. Petersen LR, Fischer M. Unpredictable and difficult to control-the adolescence of West Nile virus. N Engl J Med 2012; 367: 1281-84.
62. Nash D, Mostashari F, Fine A., et al The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 2001; 344: 1807-14.
63. Lindsey NP, Staples JE, Lehman J.A., Fischer M. Centers for Disease Control and Prevention (CDC). Surveillance for human West Nile virus disease-United States, 1999-2008. MMWR Surveill Summ 2010; 59: 1-17.
64. Centers for Disease Control and Prevention. West Nile virus disease cases reported to CDC by state, 1999-2013. Data from ArboNET. http://www.cdc.gov/ westnile/resources/pdfs/cummulative/99-2013-cummulativeHumanCases.pdf (accessed June 19, 2014).
65. Petersen LR, Carson PJ, Biggerstaff B.J., Custer B., Borchardt SM, Busch MP Estimated cumulative incidence of West Nile virus infection in US adults, 1999-2010. Epidemiol Infect 2013; 141: 591-95.
66. Roehr B. Texas records worst outbreak of West Nile Virus on record. BMJ 2012; 345: e6019.
67. Mostashari F, Bunning ML, Kitsutani P.T., et al Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 2001; 358: 261-64.
68. Bhatt S, Gething P W, Brady OJ, et al The global distribution and burden of dengue. Nature 2013; 496: 504-07.
69. Centers for Disease Control and Prevention. Notes from the field: dengue epidemic-Puerto Rico, January-July 2010. MMWR Morb Mortal Wkly Rep 2010; 59: 878.
70. Centers for Disease Control and Prevention. Locally acquired dengue-Key West, Florida, 2009-2010. MMWR Morb Mortal Wkly Rep 2010; 59: 577-81.
71. Pan American Health Organization, Centers for Disease Control and Prevention. Preparedness and response for chikungunya virus. Introduction in the Americas. Washington, DC: PAHO, 2011.
72. Burt FJ, Rolph MS, Rulli N.E., Mahalingam S., Heise MT Chikungunya: a re-emerging virus. Lancet 2012; 379: 662-71.
73. Fischer M, Staples JE Notes from the field: Chikungunya virus spreads in the Americas-Caribbean and South America, 2013-2014. MMWR; 63: 500-01.
74. Hoen AG, Margos G, Bent S.J., et al Phylogeography of Borrelia burgdorferi in the eastern United States reflects multiple independent Lyme disease emergence events. Proc Natl Acad Sci USA 2009; 106: 15013-18.
75. Centers for Disease Control and Prevention. Summary of notifiable diseases-United States, 2010. MMWR Morb Mortal Wkly Rep 2012; 59: 1-111.
76. Demma LJ, Traeger MS, Nicholson W.L., et al Rocky Mountain spotted fever from an unexpected tick vector in Arizona. N Engl J Med 2005; 353: 587-94.
77. Demma LJ, Traeger M, Blau D., et al Serologic evidence for exposure to Rickettsia rickettsii in eastern Arizona and recent emergence of Rocky Mountain spotted fever in this region. Vector Borne Zoonotic Dis 2006; 6: 423-29.
78. Todd SR, Drexler NI, Brock A, et al Extreme Rodeo: results of a Rocky Mountain spotted fever intervention project-eastern Arizona, 2012. 62nd Epidemic Intelligence Service (EIS) conference; Atlanta, GA; April 22-26, 2013. Abstract, page 72. http://www.cdc.gov/eis/downloads/2013-EIS-Conference.pdf (accessed June 18, 2014).
79. Pritt BS, Sloan LM, Johnson D.K., et al Emergence of a new pathogenic Ehrlichia species, Wisconsin and Minnesota, 2009. N Engl J Med 2011; 365: 422-29.
80. McMullan LK, Folk SM, Kelly A.J., et al A new phlebovirus associated with severe febrile illness in Missouri. N Engl J Med 2012; 367: 834-41.
81. Centers for Disease Control and Prevention. National capacity for surveillance, prevention, and control of West Nile virus and other arbovirus infections-United States, 2004 and 2012. MMWR Morb Mortal Wkly Rep 2014; 63: 281-84.
82. Scallan E, Hoekstra RM, Angulo F.J., et al Foodborne illness acquired in the United States-major pathogens. Emerg Infect Dis 2011; 17: 7-15.
83. Scallan E, Griffin PM, Angulo F.J., Tauxe RV, Hoekstra RM Foodborne illness acquired in the United States-unspecified agents. Emerg Infect Dis 2011; 17: 16-22.
84. Centers for Disease Control and Prevention. Surveillance for foodborne disease outbreaks-United States, 2007. MMWR Morb Mortal Wkly Rep 2010; 59: 973-79.
85. Lipkin WI. The changing face of pathogen discovery and surveillance. Nat Rev 2013; 11: 133-41.
86. Centers for Disease Control and Prevention. Vital signs: incidence and trends of infection with pathogens transmitted commonly through food: foodborne diseases active surveillance network, 10 US sites, 1996-2010. MMWR Morb Mortal Wkly Rep 2011; 60: 749-55.
87. Centers for Disease Control and Prevention. Incidence and trends of infection with pathogens transmitted commonly through food-foodborne diseases active surveillance network, 10 U.S. sites, 1996-2012. MMWR Morb Mortal Wkly Rep 2013; 62: 283-87.
88. Centers for Disease Control and Prevention. Incidence and trends of infection with pathogens transmitted commonly through food-foodborne diseases active surveillance network, 10 U.S. sites, 2006-2013. MMWR Morb Mortal Wkly Rep 2014; 63: 328-32.
89. Painter JA, Hoekstra RM, Ayers T, et al Attribution of foodborne illnesses, hospitalizations, and deaths to food commodities by using outbreak data, United States, 1998-2008. Emerg Infect Dis 2013; 19: 407-15.
90. Cronquist AB, Mody RK, Atkinson R, et al Impacts of culture-independent diagnostic practices on public health surveillance for bacterial enteric pathogens. Clin Infect Dis 2012; 54 (suppl 5): S432-39.
91. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data-United States and 6 U.S. dependent areas-2011. HIV Surveill Supplemental Rep 2013; 18.
92. Hall HI, Song R, Rhodes P., et al, for the HIV Incidence Surveillance Group. Estimation of HIV incidence in the United States. JAMA 2008; 300: 520-29.
93. Centers for Disease Control and Prevention. Estimated HIV incidence in the United States, 2007-2010. HIV Surveillance Report 2012; 17. http://www.cdc.gov/hiv/pdf/statistics-hssr-vol-17-no-4.pdf (accessed June 19, 2014).
94. Centers for Disease Control and Prevention. Testing makes us stronger. http://hivtest.cdc.gov/stronger/index.html (accessed June 18, 2014).
95. Branson BM, Handsfield HH, Lampe M.A., et al Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55 (RR-14): 1-17.
96. Cohen MS, Chen YQ, McCauley M, et al Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
97. Baeten JM, Donnell D, Ndase P., et al Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367: 399-410.
98. Hall HI, Frazier EL, Rhodes P, et al Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med 2013; 173: 1337-44.
99. White House Office of National AIDS Policy. National HIV/AIDS strategy for the United States. Washington, DC: The White House; July 13, 2010. http://www.whitehouse.gov/sites/default/files/uploads/NHAS.pdf (accessed June 19, 2014).
100. Centers for Disease Control and Prevention. High impact HIV prevention. CDC's approach to reducing HIV infections in the United States. Atlanta, GA; Centers for Disease Control and Prevention, 2011. http://www.cdc.gov/hiv/pdf/ policies-NHPC-Booklet.pdf (accessed May 17, 2013).
101. Herbst JH, Glassman M, Carey J.W., et al Operational research to improve HIV prevention in the United States. J Acquir Immune Defic Syndr 2012; 59: 530-36.
102. Owusu-Edusei K Jr, Chesson HW, Gift TL, et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis 2013; 40: 197-201.
103. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2012. Atlanta, GA; US Department of Health and Human Services, 2013. http://www.cdc.gov/std/stats12/Surv2012.pdf (accessed June 19, 2014).
104. Bolan GA, Sparling PF, Wasserheit JN The emerging threat of untreatable gonococcal infection. N Engl J Med 2012; 66: 485-87.
105. Centers for Disease Control and Prevention. CDC Grand Rounds: the growing threat of multidrug-resistant gonorrhea. MMWR Morb Mortal Wkly Rep 2013; 62: 103-06.
106. Centers for Disease Control and Prevention. Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012; 61: 590-94.
107. Centers for Disease Control and Prevention. Disease burden from viral hepatitis A, B, and C in the United States, 2012. http://www.cdc.gov/hepatitis/ pdfs/disease-burden.pdf (accessed June 19, 2014).
108. Tohme RA, Xing J, Liao Y., Holmberg SD Hepatitis C testing, infection, and linkage to care among racial and ethnic minorities in the United States, 2009-2010. Am J Public Health 2013; 103: 112-19.
109. Centers for Disease Control and Prevention. Viral hepatitis populations. Asian & Pacific Islanders. http://www.cdc.gov/hepatitis/Populations/api.htm (accessed June 19, 2014).
110. Department of Health and Human Services. Action plan for the prevention, care and treatment of viral hepatitis 2014-2016. 2014. http://aids.gov/pdf/ viral-hepatitis-action-plan.pdf (accessed June 18, 2014).
111. Smith BD, Morgan RL, Beckett G.A., et al Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61 (RR-04): 1-32.
112. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998; 47 (RR-19): 1-39.
113. Centers for Disease Control and Prevention. Vital signs: evaluation of hepatitis C virus infection testing and reporting-eight U.S. Sites, 2005-2011. MMWR Morb Mortal Wkly Rep 2013; 62: 357-61.
114. Ward JW. The epidemiology of chronic hepatitis C and one-time hepatitis C virus testing of persons born during 1945 to 1965 in the United States. Clinics Liver Dis 2013; 17: 1-11.
115. Rein DB, Smith BD, Wittenborn J.S., et al The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156: 263-70.
116. Centers for Disease Control and Prevention. Trends in tuberculosis-United States, 2012. MMWR Morb Mortal Wkly Rep 2013; 62: 201-05.
117. Centers for Disease Control and Prevention. Tuberculosis outbreak associated with a homeless shelter-Kane County, Illinois, 2007-2011. MMWR Morb Mortal Wkly Rep 2012; 61: 186-89.
118. Centers for Disease Control and Prevention. Notes from the field: tuberculosis cluster associated with homelessness-Duval County, Florida, 2004-2012. MMWR Morb Mortal Wkly Rep 2012; 61: 539-40.
119. Reves RR, Nolan CM Tuberculosis elimination in the United States: an achievable goal or an illusion? Am J Respir Crit Care Med 2012; 186: i-iii.
120. Gordin FM, Masur H. Current approaches to tuberculosis in the United States. JAMA 2012; 308: 283-89.
121. Luetkemeyer AF. Current issues in the diagnosis and management of tuberculosis and HIV coinfection in the United States. Top HIV Med 2010; 18: 143-48.
122. US Food Drug and Administration. FDA approves first drug to treat multi-drug resistant tuberculosis [press release]. Silver Spring, MD: Food an d Drug Administration; Dec 31, 2012.
123. Frieden TR, Tappero JW, Dowell S.F., Hien NT, Guillaume FD, Aceng JR Safer countries through global health security. Lancet 2014; 383: 764-66.
124. Relman DA. Microbial genomics and infectious diseases. N Engl J Med 2011; 365: 347-57.
125. Koser CU, Ellington MJ, Cartwright EJP, et al Routine use of microbial whole genome sequencing in diagnostic and public health microbiology. Plos Pathog 2012; 8: e1002824.
126. Snitkin ES, Zelazny AM, Thomas P.J., et al Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoinae with whole-genome sequencing. Sci Transl Med 2012; 4: 148ra116.
127. Relman DA. Metagenomics, infectious disease diagnostics, and outbreak investigations: sequence first, ask question later? JAMA 2013; 309: 1531-32.
128. Lemon KP, Armitage GC, Relman D.A., Fischback MA Microbiota-targeted therapies: an ecological perspective. Sci Transl Med 2012; 4: 137rv5.